Latest Breaking News On - கிறிஸ் சென் - Page 11 : comparemela.com
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies, today announced that OBT has selected a second bispecific program that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology (IO) candidate, OX003. OBT will research and develop OX003/PD-L1, which employs WuXi Biologics’ proprietary bispecific antibody platform WuXiBody®.
Wuxi
Jiangsu
China
Germany
Shanghai
United-states
New-jersey
United-kingdom
Singapore
California
Ireland
Oxford-biotherapeutics
Press release content from Business Wire. The AP news staff was not involved in its creation.
Hongqi Exhibition Hall Kuwait Opens With The Launch of Three Products
January 8, 2021 GMT
Hongqi Exhibition Hall in Kuwait opened, and three models H9, H5 and HS5 were launched for Kuwaiti users. (Photo: Business Wire)
Hongqi Exhibition Hall in Kuwait opened, and three models H9, H5 and HS5 were launched for Kuwaiti users. (Photo: Business Wire)
KUWAIT CITY (BUSINESS WIRE) Jan 8, 2021
Hongqi Exhibition Hall in Kuwait opened, and three models H9, H5 and HS5 were launched for Kuwaiti users. H9 makes its debut in Kuwait, which is its second debut in the Middle East after its release in Dubai.
China
Dubai
Dubayy
United-arab-emirates
Changchun
Jilin
Kuwait
Kuwaiti
Chinese
Chris-chen
Cheng-yongru
Yang-dayong
vimarsana © 2020. All Rights Reserved.